Skip to content

Therapeutic effects of single and divided doses of piracetam for children with breath holding spells

Evaluation of therapeutic effects of single and divided dose of piracetam in patients with breath holding spells

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016060612782N11
Enrollment
50
Registered
2017-03-10
Start date
2016-08-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breath holding. Other and unspecified abnormalities of breathing

Interventions

Intervention 1: Control group: 40 mg/kg piracetam single dose daily. Intervention 2: Intervention group: 40 mg/kg Piracetam in two doses every 12 hours.
Treatment - Drugs
Control group: 40 mg/kg piracetam single dose daily
Intervention group: 40 mg/kg Piracetam in two doses every 12 hours

Sponsors

Vice Chancellor for research of Isfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Months to 3 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria for the study included as follows: Age of 6 months to three years; Frequent seizures, more than two times a week; Severe seizures that lead to loss of consciousness Exclusion criteria included as follows: History of seizures; History of heart disease; Anemia (hemoglobin less than 10.5)

Exclusion criteria

Exclusion criteria:

Design outcomes

Secondary

MeasureTime frame
Drug side effects. Timepoint: once in any month for 4 months. Method of measurement: examamination and ask from mother.

Primary

MeasureTime frame
Number of breath holding. Timepoint: once in any month for 4 months. Method of measurement: ask from mother.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Akbar Azimi

Isfahan University of Medical Sciences

azimi.akbar92@yahoo.com+98 31 3226 0304

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026